Recursion Pharmaceuticals Inc - Class A (RXRX) Financial Statements

RXRX Financial Data

EBITDA$-458.95M

Revenue (TTM)$66.41M

Gross Profit (TTM)$4.79M

Gross Margin—

Operating Margin-867.87%

ROE-49.50%

ROA-37.97%

Debt/Equity0.07

Current Ratio5.50

FCF$-378.28M

FCF Yield-24.48%

Piotroski F-Score—

Rev/Share (TTM)$0.13

50-Day MA$3.34

200-Day MA$4.38

Shares Outstanding0.53B

RXRX Computed Insights

FCF$-378.28M

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

RXRX Financial Statements & Data

Recursion Pharmaceuticals Inc - Class A (RXRX) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Recursion Pharmaceuticals Inc - Class A's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $66.41M. Gross profit (TTM) is $4.79M. EBITDA is $-458.95M. Earnings per share (EPS) is $-1.44. The P/E ratio is -2.76. Market capitalization is $1.55B.

Free cash flow (FCF) is $-378.28M. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Recursion Pharmaceuticals Inc - Class A's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.